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Abstract
We have previously reported that galectin 1 (Gal-1) plays important biological roles in astroglial as well as in oligo-
dendroglial cancer cells. As an oligodendroglioma model, we make use of the Hs683 cell line that has been pre-
viously extensively characterized at cell biology, molecular biology, and genetic levels. Galectin 1 has been shown
to be involved in Hs683 oligodendroglioma chemoresistance, neoangiogenesis, and migration. Down-regulating
Gal-1 expression in Hs683 cells through targeted small interfering RNA provokes a marked decrease in the expres-
sion of the brain-expressed X-linked gene: BEX2. Accordingly, the potential role of BEX2 in Hs683 oligodendrogli-
oma cell biology has been investigated. The data presented here reveal that decreasing BEX2 expression in Hs683
cells increases the survival of Hs683 orthotopic xenograft-bearing mice. Furthermore, this decrease in BEX2 ex-
pression impairs vasculogenic mimicry channel formation in vitro and angiogenesis in vivo, and modulates glioma
cell adhesion and invasive features through the modification of several genes previously reported to play a role in
cancer cell migration, including MAP2, plexin C1, SWAP70, and integrin β6. We thus conclude that BEX2 is impli-
cated in oligodendroglioma biology.
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Introduction
Gliomas are the most common primary brain malignancy found in
adults [1,2]. High-grade gliomas of astrocytic origin are characterized
by the diffuse invasion of distant brain tissue by a myriad of single
migrating cells with reduced susceptibility to apoptosis and conse-
quent resistance to the cytotoxic insults of proapoptotic drugs [2].
Current recommendations are that patients with high-grade astro-
gliomas (including glioblastoma multiforme, GBM) should undergo
maximum surgical resection, followed by concurrent radiation and
chemotherapy with the alkylating drug temozolomide (TMZ) [3].
Oligodendrogliomas are rare and diffusely infiltrating tumors arising
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in the white matter of cerebral hemispheres and display better sensi-
tivity to treatment and a better prognosis than other gliomas [4].
Chronic platelet-derived growth factor signaling in glial progeni-
tors leads to the formation of oligodendrogliomas in mice, whereas
chronic combined Ras and Akt signaling leads to astrocytomas [5].
The different histologies of these tumors imply that the pathways ac-
tivated by these two oncogenic stimulations are different and that the
apparent lineage of the tumor cells may result from specific signaling
activity [5]. Combined activation of Ras and AKT leads to the for-
mation of astrocytic GBM in mice [6]. In human GBMs, AKT is not
mutated but is activated in approximately 70% of these tumors, in
association with loss of PTEN and/or activation of receptor tyrosine
kinases [6]. Oligodendrogliomas with 1p19q codeletion harbor a
gene expression profile that partially resembles the gene expression
of normal brain samples, whereas gliomas with epidermal growth fac-
tor receptor amplification express many genes in common with glio-
blastoma cancer stem cells [7]. Neuronal differentiation could occur
in oligodendrogliomas with 1p19q codeletion and the cell of origin
for gliomas with 1p19q codeletion could be a bipotential progenitor
cell, able to give rise to both neurons and oligodendrocytes [7].
Galectin 1 (Gal-1) belongs to a family of 15 carbohydrate-binding
proteins with affinity for β-galactosides [8,9] and has been shown to
play an important role in astroglioma and oligodendroglioma cell
biology [9]. For example, Gal-1 is a key player in astroglioma and
oligodendroglioma cell migration [10–12]. Galectin 1 expression is
increased under hypoxic conditions [13], and radiotherapy stimulates
Gal-1 expression in glioma cells [14].
We have recently demonstrated that TMZ stimulates Gal-1 expres-
sion in the Hs683 oligodendroglioma model [15] and that decreasing
Gal-1 expression in these Hs683 cells increases the antitumor effects
contributed by TMZ both in vitro and in vivo [15,16].
Galectin 1 is a key player in tumor neoangiogenesis [17], and we
have recently demonstrated that Gal-1 exerts its proangiogenic ef-
fects in human Hs683 oligodendrogliomas through the endoplasmic
reticulum transmembrane kinase/ribonuclease inositol-requiring 1α
(IRE-1α)–mediated control of the expression of oxygen-related pro-
tein 150, which, in turn, controls vascular endothelial growth factor
(VEGF) maturation [16].
We observed that down-regulating Gal-1 expression in Hs683 hu-
man oligodendroglioma cells through targeted small interfering RNA
(siRNA) provokes a marked decrease in the expression of the brain-
expressed X-linked gene. BEX2, which belongs to a small family of
six genes with a wide distribution among tissue types [18,19], is
found highly expressed in the embryonic brain [20]. BEX2 is de-
scribed as a tumor suppressor gene in astrogliomas [21] and has been
implicated in apoptotic features of breast cancer [22]. The role of
BEX2 in oligodendroglioma biology has never been investigated, at
least to the best of our knowledge, and therefore represents the aim
of the present work. As a human oligodendroglioma model, we made
use of the Hs683 cell line, whose oligodendroglial origin has been
extensively characterized. Indeed, Hs683 tumor cells are 1p19q co-
deleted [23] and are highly sensitive to chemotherapy under in vivo
orthotopic brain xenograft conditions [23]. These cells display very
weak (if any) vimentin expression and high levels of integrin β4 ex-
pression [24] as do oligodendrogliomas [24,25]. Hs683 cells do not
express the human 1p-distal ATAD 3B gene, which is highly ex-
pressed in astroglioma cells [26]. However, they contain only one
Notch2 gene copy per diploid genome as do oligodendrogliomas
[27], in which loss of the 1p centromeric marker within intron 12
of the Notch2 gene is associated with a favorable prognosis in oligo-
dendroglioma patients [28,29].
Materials and Methods
Cell Cultures and Compounds
The Hs683 (ATCC code HTB-138), U87 (ATCC code HTB-
14), U373 (ATCC code HTB-17), and T98G (ATCC code CRL-
1690) human glioma cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA) and maintained in
our laboratory as detailed previously [15,16,23,24].
We also made use of four primocultures established in our facilities as
detailed previously [30]. Briefly, glioma tumor specimens were trans-
ferred during surgery into culture medium (RPMI-1640 with 20%
fetal calf serum [FCS], 1% glutamine, 1% penicillin/streptomycin).
The tissue was gently disrupted and washed with physiological saline
to remove red blood cells. After passage 5, cells were grown in a cul-
ture medium containing 10% FCS without antibiotics. These primo-
cultures have been labeled GL-5, GL-16, GL-17, and GL-19 in the
current study. They are part of a collection of several hundred glioma
primocultures established in the Department of Neurosurgery of the
Wagner Jauregg Hospital (Linz, Austria).
Anti–Gal-1 siRNA and Anti-BEX2 siRNA
The sequence of the siRNA (Eurogentec, Seraing, Belgium) used
in the current work are listed below. For Gal-1, the sense sequence was
5′-gcugccagauggauacgaadtdt-3′ and the antisense sequence was 5′-
uucguauccaucuggcagcdtdt-3′ [15,16]. For BEX2, the sense sequence
was 5′-gcaggagaguuuuaccuaudtdt-3′ and the antisense sequence was
5′-auagguaaaacucuccugcdtdt-3′. A corresponding nonspecific sequence
siRNA (designated throughout as CT siRNA) was used as a process
control (sense, 5′-ggaaaucccccaacagugadtdt-3′; antisense, 5′-ucacuguu-
gggggauuuccdtdt-3′). The antisense and sense strands of the siRNA
were annealed by the manufacturer in 50 mM Tris, pH 7.5 to 8.0,
and 100 mM NaCl in diethylpyrocarbonate–treated water. The final
concentration of siRNA duplexes was 100 μM.
Hs683 glioma cells were either left untreated (wild type: wt) or
were transfected with calcium phosphate (Kit ProFection mammalian
transfection system; Promega, Leiden, the Netherlands) containing
the specified siRNA for 16 hours (day 0). On day 1, the transfection
procedure was repeated. On day 2, each group of cells was pooled
and replated for subsequent experiments. On days 5, 7, 9, 12, and
14, Hs683 cells were either scraped into cold PBS buffer (for RNA
extraction) or lysed directly in boiling lysis buffer (10 mM Tris pH 7.4,
1 mM Na3VO4, 1% SDS, pH 7.4) for protein extraction. Hs683 cells
were also cultured on glass coverslips for immunofluorescence (IF)
analyses as detailed previously [15,16]. The efficiency of the anti–
Gal-1 siRNA was evaluated by means of Western blot (WB) analysis
and/or IF and the efficiency of the anti-BEX2 siRNA was evaluated
by means of IF and/or reverse transcription–polymerase chain reac-
tion (RT-PCR).
In Vitro Transfection of Anti-BEX2 siRNA into Hs683
Cells and Their Grafting into the Brains of
Immunocompromised Mice
Hs683 glioma cells were transfected in vitro with anti-BEX2 siRNA
or CT siRNA as detailed above. Hs683 cells were grafted orthotop-
ically into the brains of nude mice as described previously [31]. In
each experiment, all mice (8-week-old female nu/nu mice, 21-23 g; Iffa
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Credo, Charles Rivers, Arbresle, France) had 100,000 Hs683 cells
(wt, CT siRNA-transfected, or anti-BEX2 siRNA-transfected) stereo-
tactically implanted on the same day (day 5 after siRNA transfection).
Each experimental group contained 11 mice. All the in vivo experi-
ments described in the present study were performed on the basis of
Authorization No. LA1230509 of the Animal Ethics Committee of
the Federal Department of Health, Nutritional Safety and the Envi-
ronment (Belgium).
In Vivo Determination of Tumor Neoangiogenesis
Each mouse bearing a brain Hs683 glioma underwent euthanasia
(in a CO2 atmosphere) for ethical reasons when it had lost 20% of its
body weight compared with that recorded on the day of tumor graft-
ing. The brain was removed from the skull, fixed in buffered formalin
for 48 hours, embedded in paraffin, and cut into 5-μm-thick sections.
After heat-induced antigen retrieval in citrate buffer (pH 6.0), sec-
tions were exposed to 0.4% hydrogen peroxide for 30 minutes to
quench endogenous peroxydase. The sections were then incubated with
an anti-CD34 antibody (diluted 1:25; Abcam, Cambridge, United
Kingdom) for 1 hour at room temperature. For visualization of anti-
gen location, the Poly-HRP IHC Detection Systems (ImmunoLogics,
Duiven, theNetherlands)method and 3,3′-diaminobenzidine (Biogenex,
Klinipath, Olen Belgium) were used. Finally, the sections were conter-
stained with hematoxylin.
The stained blood vessels were counted using a grid as indicated
previously [31,32]. Typical blood vessels analyzed are illustrated
in Figure 3B. Fifteen fields at a G×40 magnification were analyzed
per histological slide, giving thus a total of 165 histological fields
per group.
In Vitro Determination of the Capacity of Hs683 Cells to
Undergo Vasculogenic Mimicry
Petri dishes, 35 mm in diameter, were precoated with Matrigel
and then incubated at 37°C for 10 minutes. Hs683 wild-type cells,
transfected with CT siRNA or transfected with anti-BEX2 siRNA
(400,000 cells per Petri dish) were seeded on the coated Petri dishes
at day 5 after transfection and cultivated for 48 hours. The ability of
these cells to perform vasculogenic mimicry-like processes was as-
sessed qualitatively at 24 and 48 hours after seeding as described pre-
viously [16].
In Vitro Determination of Anchorage-Dependent Cell Growth
Anchorage-dependent cell growth was assessed using the 3-[4,5-
dimethylthiazol-2yl]-diphenyltetrazolium bromide (MTT; Sigma,
Bornem, Belgium) colorimetric assay, as detailed elsewhere [33].
All determinations were carried out in sextuplicate.
In Vitro Determination of Anchorage-Independent
Cell Growth
Anchorage-independent cell growth was assessed using the soft
agar clonogenic assay as previously described [34]. All determinations
were carried out in sextuplicate.
In Vitro Quantitative Determination of Cell Migration
Cell motility was characterized using computer-assisted phase-
contrast microscopy (quantitative videomicroscopy), which enables
the trajectories of living cells maintained in culture to be quantified
[33,35]. The greatest linear distance migrated by each cell (out of
hundreds of cells analyzed per experimental condition) was calculated
from these trajectories [33,35]. All experiments were performed for
72 hours with one image recorded every 4 minutes. All determina-
tions were carried out in triplicate.
In Vitro Determination of Hs683 Cell-Invasive Features
Invasive features of Hs683 cells in vitro were assessed by means of
the Boyden transwell invasion system (BD BioCoat Matrigel inva-
sion chambers; BD Biosciences Discovery Labware, Bedford, MA)
as detailed elsewhere [35].
In Vitro Adhesion Assay
The adhesion assay was performed as described previously [36]
with modifications. Six-well plates were precoated with Matrigel (di-
luted 1:3 in RPMI culture medium with 10% FCS) or with 10 μg/ml
of the 120-kDa fragment of fibronectin (Chemicon, Biognost,Waterven,
Belgium) for 1 hour at 37°C. The wells were washed, and nonspecific
binding was then blocked with 0.1% BSA in PBS for 30 minutes.
Hs683 cells (100,000 cells per well) were allowed to adhere for 1 hour
at 37°C, after which nonadherent cells were gently washed away with
warm PBS. Adherent cells were formalin-fixed, hematoxylin-stained,
and counted in 10 fields per well at a G×10 magnification using an
Olympus microscope (Olympus, Antwerp, Belgium).
Determination of BEX1 and BEX2 Genomic Expression in a
Clinical Series of 153 Gliomas and 23 Normal Brain Samples
The genomic expression of BEX1 and BEX2 was analyzed in a se-
ries of 176 human brain samples, including 23 normal brain tissues,
7 grade 2 astrocytomas, 19 grade 3 astrocytomas, 77 GBMs, 38 grade
2 oligodendrogliomas, and 12 grade 3 oligodendrogliomas. Micro-
array data were generated by the Henry Ford Hospital (Detroit,
MI) from the Affymetrix Array Series GSE4290: http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE4290.
Genomic and Proteomic Analyses
Genomic analyses RNA was extracted from wt Hs683 cells or
from those transfected with CT siRNA or specific siRNA directed
against Gal-1 or BEX2, and the quality and integrity of the extracted
RNA was assessed as detailed previously [33,35]. Full genome anal-
yses were performed on day 5 of transfection at the VIB Microarray
Facility (UZ Gasthuisberg, Catholic University of Leuven, Leuven,
Belgium) using the Affymetrix Human Genome U133 set Plus 2.0
(High Wycome, UK). Microarray data analyses were undertaken as
detailed previously [15,16,32].
Protein expression measurements Western blot and IF analyses
were performed as detailed previously [16,31–33]. Control experi-
ments included the omission of the incubation step with the pri-
mary antibodies (negative control). Equal loading was verified by
the bright Ponceau red coloration of the membranes. The integrity
and quantity of the extracts were assessed by means of tubulin immu-
noblot analysis. The following primary antibodies were used for WB
analysis: anti–Gal-1 (dilution 1:1000; Preprotech TebuBio, Boechout,
Belgium), anti–integrin β6 (dilution 1:100; Calbiochem, VWR Inter-
national, Leuven, Belgium), anti-plexinC1 (dilution 1:1000; R&D
Systems, Abingdon, United Kingdom), anti-VEGF (dilution 1:500;
Santa Cruz; TebuBio), anti–switch-associated protein 70 (SWAP70; di-
lution 1:500; Novus Biologicals; DivBioscience, Breda, the Netherlands),
and anti–IRE-1α (dilution 1:500; Cell Signaling, Bioké, Leiden, the
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Netherlands). Secondary antibodies were purchased from Pierce
(PerbioScience, Erembodegem, Belgium) for the WB s and from
Molecular Probes (Invitrogen, Merelbeke, Belgium) for fluorescent
detection (Alexa Fluor–conjugated antibodies).
Western blots were developed using the Pierce Supersignal Chemi-
luminescence system (Pierce, Perbio Science N.V., Aalst, Belgium).
The staining patterns were also assessed by immunofluorescence for
BEX2 (dilution 1:50; Abcam) and integrin β6 (dilution 1:50) and
were analyzed by means of a computer-assisted fluorescent Olympus
AX70 microscope (Omnilabo, Antwerp, Belgium) equipped with a
MegaView2 digital camera and analysis software (Soft Imaging System,
Munster, Germany), as detailed previously [16,33,35].
Reverse Transcription–Polymerase Chain Reaction
The procedure used for the standard RT-PCR was identical to that
described previously [33,35]. The following primers were used: BEX2
forward 5′-gtgatcggccaacact-3′ and reverse 5′-tccaagcctatgcattatgtc-3′,
BEX1 forward 5′-tagatgggaatatgatgcatagg-3′ and reverse 5′-caggtaaag-
gtttacaacaagg-3′, actin forward 5′-ctaagtcatagtccgcctag-3′ and reverse
5′-aaatcgtgcgtgacattaagg-3′, and Gal-1 forward 5′-agcaacctgaatct-
caaacc-3′ and reverse 5′-cttgaattcgtatccatctgg-3′. The PCR conditions
for all primer pairs, except actin, were predenaturation: 4 minutes,
94°C, PCR amplification: 35 cycles at 94°C, 30 seconds (denatura-
tion), 59°C, 30 seconds (annealing), 72°C, 1 minute (extension); and
final extension: 1 cycle at 72°C, 10 minutes. For actin, the PCR con-
ditions were predenaturation: 4 minutes, 94°C, PCR amplification:
25 cycles at 94°C, 30 seconds (denaturation), 62°C, 30 seconds (an-
nealing), 72°C, 1 minute (extension); and final extension: 1 cycle at
72°C, 10 minutes.
Statistical Analyses
Survival analyses were carried out by means of Kaplan-Meier
curves, which were compared with the log-rank test. Statistical com-
parisons between control and treated groups were established by car-
rying out the Kruskal-Wallis test (a nonparametric one-way analysis
of variance). When this multigroup test was significant, post hoc tests
(Dunn procedure) were used to compare the group pairs of interest,
thus avoiding multiple comparison effects. Data correlation was ana-
lyzed by means of the nonparametric Spearman correlation index and
its associated statistical test. All the statistical analyses were realized
using Statistica (Statsoft, Tulsa, OK).
Results
BEX1 and BEX2 Expression in Human Malignant Gliomas
and Human Normal Brain Tissues
We first analyzed the genomic expression of BEX2 and its closely
related family member BEX1 in a series of glioma and normal brain
tissue samples, and we observed that BEX1 genomic expression ap-
preciably correlated to BEX2 genomic expression in gliomas (r =
0.71; P < .001 Spearman test; Figure 1A). However, the patterns
of BEX1 and BEX2 expression differed as illustrated in Figure 1, B
and C . Indeed, whereas BEX1 expression gradually decreased accord-
ing to the sequence normal > oligodendrogliomas > astrocytomas >
highly malignant astrogliomas (Figure 1B), BEX2 expression was
globally lower in all glioma groups when compared with normal
brain tissues (Figure 1C ), with the exception that expression in the
oligodendroglioma grade 2 group was higher than that in glioblasto-
mas (Figure 1C ).
Figure 1. (A) Comparison of BEX1 versus BEX2 genomic expres-
sion in a series of 153 human glioma samples (see A and B).
BEX1 (B) and BEX2 (C) genomic expression analyzed in 23 normal
brain tissue samples (NB), 7 grade 2 astrocytomas (A2), 19 grade 3
astrocytomas (A3), 77 GBMs, 38 grade 2 oligodendrogliomas
(OD2), and 12 grade 3 oligodendrogliomas (OD3). Each case is
symbolized by a black dot, and the bars represent median values.
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Decreasing Gal-1 Expression in Hs683 Oligodendroglioma
Cells Induces a Decrease in BEX2 Expression
BEX1 and BEX2 are 85% identical [18], and therefore, to ensure
that we pursued our studies solely on BEX2, BEX1 versus BEX2 expres-
sion was analyzed (by means of an RT-PCR technique) in four human
permanent cell lines from the ATCC (including the Hs683 oligoden-
droglioma model) and in four astroglioma primocultures. Figure 2A
shows that the oligodendroglioma Hs683 cell line and the U373
and T98G astroglioma cell lines do not express BEX1. When per-
forming genome-wide analysis of Hs683 cells transiently transfected
with siRNA targeting Gal-1 [15,16], it was observed that BEX2 was
the gene whose expression was the most modified of a series of approx-
imately 140 genes. Indeed, the levels of BEX2 mRNA were decreased
by >20-fold in anti–Gal-1–transfected Hs683 cells compared with
wt or CT siRNA-transfected cells as revealed in the whole-genome
Affymetrix analysis or here by means of PCR analysis (Figure 2B).
The decrease of BEX2 expression in anti–Gal-1–transfected cells was
also confirmed by means of quantitative RT-PCR (data not shown).
Confirmation That the siRNA Approach Decreases BEX2
Expression in Hs683 Cells
Figure 2C shows that the anti-BEX2 siRNA we designed success-
fully decreased BEX2 mRNA levels in Hs683 oligodendroglioma
cells up to days 5 and 6 after transfection, whereas the levels of
Gal-1 mRNA remained unchanged. The levels of BEX2 protein
(quantitatively determined by means of computer-assisted fluores-
cence microscopy) were also significantly decreased up to day 7 after
transfection (Figure 2D). Additional experiments showed that the de-
crease in BEX2 mRNA levels in Hs683 cells lasted for 8 to 9 days
(data not shown).
Decreasing BEX2 Expression in Hs683 Cells Increases the
Survival of Hs683 Orthotopic Xenograft-Bearing Mice
Immunocompromised mice grafted with Hs683 oligodendroglioma
cells transfected with anti-BEX2 siRNA revealed a significant (P < .05)
but modest increase in survival (blue circles) compared with mice
grafted with wt (black circles) or CT siRNA-transfected Hs683 cells
Figure 2. (A) Expression of BEX1 and BEX2 mRNA in eight different human glioma cell lines (four established cell lines, namely, Hs683,
U373, T98G, and U87, and four primocultures, namely, GL-5, GL-16, GL-17, and GL-19) assessed by RT-PCR. (B) Expression of BEX2
mRNA in human Hs683 cells: wild-type non-transfected (wt), CT siRNA-transfected (CT siRNA), or anti–Gal-1 siRNA-transfected (aGal-1–
siRNA) on days 7 and 9 after transfection, assessed by RT-PCR. (C) Expression of BEX2 mRNA in Hs683 cells: wild-type nontransfected
(wt), CT siRNA-transfected (CT siRNA), or anti-BEX2 siRNA-transfected (aBEX2 siRNA) on days 5 and 6 after transfection, assessed by
RT-PCR. (D) Immunofluorescence analysis of BEX2 expression in Hs683 cells on day 7 after transfection in wild-type nontransfected
(Da) or CT siRNA-transfected (Db) or anti-BEX2 siRNA-transfected (Dc). (Dd) BEX2 expression quantitatively determined by means of
computer-assisted fluorescence microscopy in wild type (wt) and transfected Hs683 cells.
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(red circles; Figure 3A). This experiment has been conducted twice with
similar results (data for the second experiment are not shown).
BEX2 Is Implicated in Hs683 Oligodendroglioma
Neoangiogenesis In Vivo
As Gal-1 has been shown to play an important role in angiogen-
esis, we investigated whether decreasing BEX2 expression in Hs683
oligodendroglioma orthotopic xenografts in immunocompromised
mice (Figure 3Ba) impaired neoangiogenesis features. For this pur-
pose, 11 mice per group orthotopically grafted with wt, control, or
anti-BEX2 siRNA–transfected Hs683 cells underwent euthanasia on
day 17 after tumor grafting. The blood vessels in the tumor were
stained by immunohistochemistry using an anti-CD34 antibody.
The typical blood vessels taken into account to assess angiogenesis
Figure 3. (A) Survival of immunocompromised mice with brain xenografts of wild-type nontransfected human Hs683 cells (red circles),
Hs683 cells transfected in vitro with CT siRNA (black circles), or anti-BEX2 siRNA (blue circles). (Ba) Morphological illustration of the
invasive patterns of Hs683 after orthotopic xenografts into the brains of immunocompromised mice (hematoxylin and eosin–stained;
magnification, ×10). NB indicates normal brain tissue; T , tumor. (Bb) Illustration of the blood vessels (black arrows) stained with an anti-
CD34 antibody in Hs683 xenografts (magnification, ×40). In this picture (wt condition), we can observe four blood vessels on one mi-
croscopic field. (C) Distribution of the blood vessel counts on 165 microscopic fields in wild type (wt: Ca), CT siRNA- (Cb), or anti-BEX2
siRNA- (Cc) transfected Hs683 orthotopic xenografts.
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in Hs683 tumors are illustrated in Figure 3Bb. Decreasing BEX2 ex-
pression in Hs683 xenografts significantly (P < .01) decreased the
number of blood vessels within these tumors (Figure 3Cc) compared
with controls (Figure 3, Ca and Cb).
Ability to Elicit Vasculogenic Mimicry Differs in Wild-type,
CT siRNA-, and Anti-BEX2 siRNA-Transfected Hs683
Cells In Vitro
Gross histological examination as performed and illustrated in
Figure 3B cannot distinguish between true angiogenesis and vasculo-
genic mimicry processes. Aggressive tumors, including, for example,
melanomas, may generate tumor cells that form vascular channels
that facilitate perfusion independent of tumor angiogenesis [37]. Vas-
culogenic mimicry has also been shown to be a feature of gliomas
[38]. In addition, we have reported previously that Gal-1 is im-
plicated in vitro in vasculogenic mimicry performed by Hs683 oli-
godendroglioma cells [16]. Accordingly, differences in the patterns
of vasculogenic mimicry between wt, CT siRNA-, and anti-BEX2
siRNA-transfected Hs683 cells were investigated. The data reveal
that when wt (Figure 4A) and control-transfected (Figure 4B) Hs683
cells were cultured on Matrigel, networking processes resembling vas-
culogenic mimicry were observed. In contrast, anti-BEX2 siRNA-
transfected Hs683 cells no longer demonstrated these vasculogenic
processes (Figure 4C). Figure 4D confirms that the siRNA against
BEX2 actually decreased its expression compared with wt and CT
siRNA-transfected Hs683 cells, although this decrease of BEX2 ex-
pression was not as strong as what was obtained with the previous
transfection (Figure 2C).
Decreasing BEX2 Expression in Hs683 Cells Impairs Their
Migration Characteristics
Reducing BEX2 expression in Hs683 cells seemed to have no im-
pact on anchorage-dependent or -independent growth, cell cycle ki-
netics or proliferation rate, cell motility when cultured on plastic or
Matrigel, susceptibility to apoptosis, or increased sensitivity to two cyto-
toxic drugs investigated (TMZ and carmustine). These data are sum-
marized for the sake of clarity in Table 1.
However, striking effects relating to cell migration including adhe-
sion and invasion were observed when decreasing BEX2 expression.
Indeed, decreasing BEX2 expression significantly (P < .001) increased
the levels of adhesion of Hs683 cells cultured in Matrigel or in fi-
bronectin (Figure 5A). In addition, although quantitative videomi-
croscopy revealed that impairing BEX2 expression did not modify
Hs683 two-dimensional cell motility when cultured on plastic or
Matrigel (Table 1), decreasing BEX2 expression significantly im-
paired their ability to invade (three-dimensional) Matrigel-coated
membranes in Boyden chamber assays (Figure 5B).
Decreasing BEX2 Expression in Hs683 Cells Modifies the
mRNA Levels of Several Genes Implicated in Cell Migration
Previous studies and present data show that 1) Gal-1 exerts potent
promigratory effects [10–12], 2) impairing Gal-1 expression reduces
BEX2 expression (Figure 2B), and 3) BEX2 seems to be implicated in
migration (Figure 5). For these reasons, we carried out microarray anal-
ysis to compare gene expression in wt, anti-BEX2 siRNA-transfected,
and control siRNA-transfected Hs683 cells. Of the 26 genes whose
expression was significantly upregulated or downregulated (i.e., ≥1.6-
or ≤0.6-fold, respectively) 8 are known to exert a role in cell migration
Figure 4.Wild-type (A) and CT siRNA-transfected (B) Hs683 cells developed vasculogenic capillary networks when cultured on Matrigel,
whereas Hs683 cells (C) transfected with anti-BEX2 siRNA did not. (D) Confirmation of decrease in BEX2 mRNA in anti-BEX2 siRNA-
transfected (aBEX2 siRNA) compared with wild-type nontransfected (wt) and CT siRNA-transfected (CT siRNA) Hs683 cells on days 5
and 7 after transfection, assessed by RT-PCR.
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(MAP2, ITGB6, VIL1, MMP7, PLXNC1, CCL2, NT5E, and
SWAP70; Table 2).
Figure 6 illustrates the data obtained at the protein level with respect
to four of the eight genes listed in Table 2: microtubule-associated pro-
tein 2 (MAP2), plexin C1, switch-associated protein 70 (SWAP70),
and integrin β6. Transiently decreasing BEX2 expression in Hs683 cells
markedly increased MAP2 expression, slightly increased plexin C1 ex-
pression, and abolished SWAP70 expression (Figure 6A). Decreasing
BEX2 expression also markedly increased integrin β6 expression
(Figure 6B). Moreover, IF analysis revealed a diffuse staining pattern
for integrin β6 in Hs683 cells transfected with control CT siRNA (Fig-
ure 6, Ca and Cb), whereas marked integrin β6 clustering at the level
of lamelipodia became apparent when decreasing BEX2 expression
(Figure 6, Cc and Cd ).
Moreover, transiently decreasing Gal-1 expression in Hs683 cells
also increased MAP2 and plexin C1 (Figure 6A). These data strongly
suggest that BEX2 could exert its modulatory influences on MAP2
and plexin C1 expression under Gal-1 control, whereas it could ex-
ert such an influence on integrin β6 and SWAP70 without Gal-1
control (Figure 6A).
Discussion
Galectin 1 has been shown to be a key player in astroglioma and
oligodendroglioma cell migration [10–12] and oligodendroglioma
neoangiogenesis [16] and chemoresistance [15]. In a previous study,
we observed that the gene whose expression is the most decreased in
response to siRNA-targeted against Gal-1 in Hs683 oligodendrogli-
oma cells is BEX2 [16]. It would also be interesting to analyze the
levels of expression of BEX2 in oligodendroglioma cell types that
are not expressing Gal-1 and to investigate whether exogenous addi-
tion of Gal-1 will stimulate BEX2 expression. However, we could not
find any oligodendroglioma (and even astroglioma) cell lines that do
not express Gal-1.
In this study, BEX2 expression has been found to be lower in glio-
blastomas than in normal brain tissues and low-grade oligodendro-
gliomas (Figure 1). This could relate to the fact that epigenetic
processes may silence BEX2 expression in glioblastomas [21]. When
Foltz et al. [21] treated astroglioma cells with trichostatin A, a histone
deacetylase inhibitor or with 5-aza-2′-deoxycytidine, a DNA methy-
transferase inhibitor, to identify epigenetically silenced genes, they
Table 1. Summary of Experiments Undertaken to Investigate BEX2-Mediated Biological Effects in Human Hs683 GBM Cells.
Cell Biology Feature Evaluated Techniques Used References Fully Detailing Technique Used Comments to Data Obtained in the Current Study
Cell population kinetics
Anchorage-dependent
global cell growth
MTT colorimetric assay [39,40] Decreasing BEX2 expression in Hs683 cells did not
modify their anchorage-dependent growth.
Anchorage-independent
cell growth
Soft-agar clonogenic assay [34] Decreasing BEX2 expression in Hs683 cells did not
modify their anchorage-independent growth.
Cell proliferation (cell
cycle kinetics)
Flow cytometry analysis of propidium
iodide–stained cells
[32] Decreasing BEX2 expression in Hs683 cells did not
modify cell cycle kinetics or their proliferation rate.
Cell death (apoptosis) Flow cytometry analysis of
TUNNEL-propidium iodide–stained cells
[32] Decreasing BEX2 expression in Hs683 cells did not
induce apoptosis.
Cell migration
Motility Computer-assisted phase-contrast
microscopy (quantitative videomicroscopy)
[10,11,35] Decreasing BEX2 expression in Hs683 cells did not
modify their motility levels when cultured on plastic
or Matrigel.
Sensitivity to anticancer drugs
Anchorage-dependent
cell growth
MTT colorimetric assay [15] Decreasing BEX2 expression in Hs683 cells did not
modify their sensitivity to the cytotoxic effects of TMZ
or BCNU.
Figure 5. (A) Characterization of the adhesive properties of wild
type (wt), control siRNA- (CT siRNA), or anti-BEX2 siRNA-transfected
(aBEX2 siRNA) Hs683 cells on fibronectin (gray bars) or on Matrigel
(black bars) supports. Values are the mean ± SEM; ***P < .001
compared with CT siRNA. (B) Characterization of Hs683 cell inva-
siveness in Boyden chambers coated with Matrigel of wild type
(wt), CT siRNA-, or anti-BEX2 siRNA-transfected cells after 24 (gray
bars) or 48 hours (black bars). Values are the mean ± SEM; ***P <
.001 compared with CT siRNA.
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identified BEX1 and BEX2 to be silenced in all tumor specimens
because of extensive promoter hypermethylation. Viral-mediated re-
expression of either BEX1 or BEX2 led to increased sensitivity to
chemotherapy-induced apoptosis and showed potent tumor suppres-
sor effects in vitro and in a xenograft mouse model in vivo [21]. In
sharp contrast to the data reported by Foltz et al., Naderi et al. [22]
could not detect any correlation in their series of breast cancers be-
tween BEX2 methylation and expression. The BEX2 promoter is not
methylated in Hs683 oligodendroglioma cells (data not shown).
Naderi et al. [22] also showed that BEX2 was overexpressed in a subset
of primary breast cancers and that this expression was necessary for the
antiapoptotic function of the nerve growth factor in C2-treated cells.
These authors suggest that the nerve growth factor/BEX2/nuclear
factor-κβ pathway could be involved in regulating apoptosis in breast
cancer cells and in modulating the response to tamoxifen in primary
breast cancers [22]. In the current study, decreasing BEX2 expression
in Hs683 oligodendroglioma cells did not increase their sensitivity to
TMZ or carmustine or lead to modifications in cell proliferation, cell
death (apoptosis), or anchorage-dependent or -independent growth
(Table 1). In addition, in contrast to the study of Foltz et al. [21],
which relied on the analysis of astroglial cells, transiently decreasing
BEX2 expression in Hs683 oligodendroglioma cells induced modest
but nevertheless significant increases in the survival of Hs683 ortho-
topic xenograft-bearing mice. It thus seems that BEX2 biological func-
tions and activity could markedly differ between astroglioma and
oligodendroglioma cells, a feature which we already emphasized in
the introduction with respect to the gene products PDGF [5], EGFR
[7], vimentin [25], integrin β4 [24], ATAD 3B [26], and Notch2 [27].
Figure 6. (A) Western blot analysis ofMAP2, plexin C1, and SWAP70 expression in wild type (wt), CT siRNA-transfected (CT siRNA), anti-
BEX2 siRNA-transfected (aBEX2 siRNA), and anti–Gal-1 siRNA-transfected (aGal-1 siRNA) Hs683 cells on day 5 after transfection. (B)
Western blot analysis of integrin β6 expression in wt, CT siRNA, aBEX2 siRNA-transfected, and aGal-1 siRNA-transfected Hs683 cells
on day 5 after transfection. (C) Immunofluorescence analysis (with bright field controls) of integrin β6 expression in CT siRNA- (Ca and
Cb) and aBEX2 siRNA-transfected (Cc and Cd) Hs683 cells on day 5 after transfection.
Table 2. Migration-Related Genes Whose mRNA Expression Was Modified in Hs683 GBM Cells with Reduced BEX2 Expression.
Official Gene Symbol Gene Name Ratio 1: wt/aBEX2 siRNA Ratio 2: CT siRNA/aBEX2 siRNA References to Cell Migration
MAP2 Microtubule-associated protein 2 0.4 0.5 [41,42]
ITGB6 Integrin beta 6 0.4 0.5 [43,44]
VIL1 Villin 1 0.4 0.5 [45,46]
MMP7 Matrix metalloproteinase 7 (matrilysin, uterine) 0.6 0.5 [47]
PLXNC1 Plexin C1 0.3 0.6 [48]
CCL2 Chemokine (C-C motif ) ligand 2 0.6 0.6 [49–51]
NT5E 5′-Nucleotidase, ecto (CD73) 1.6 1.7 [52,53]
SWAP70 SWAP-70 protein 1.6 2.1 [54,55]
Ratios of gene expression in 1) wild type (wt)/anti-BEX2 siRNA-transfected Hs683 cells and 2) CT siRNA/anti-BEX2 siRNA-transfected Hs683 cells.
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Decreasing BEX2 expression in Hs683 oligodendroglioma cells im-
pairs angiogenesis in Hs683 xenografts when these cells are orthotopically
grafted in vivo into the brains of immunocompromised mice (Fig-
ure 3). It is worthwhile to note that the type of staining we per-
formed with CD34 does not allow for differentiation between
tumor neoangiogenesis and normal vessels trapped within tumor tis-
sues. The use of antibodies directed against specific markers of tumor
endothelial cells, such as CD105 [56] or Dkk-3 [57], would be use-
ful to determine if BEX2 is indeed involved in tumor neoangiogen-
esis. However, although these markers have been proven effective to
determine neoangiogenesis through immunohistochemistry in human
tissue [56,57], we failed to be able to use these markers in the present
study to make this determination in mouse tissue (data not shown).
A previous study [16] and the current one revealed that BEX2 ex-
pression is controlled, at least partly, by Gal-1. Galectin 1 has been
shown to exert its proangiogenic effects, at least partly, through the
endoplasmic reticulum transmembrane kinase/ribonuclease IRE-1α–
mediated control of the expression of oxygen-related protein 150,
which, in turn, controls VEGF expression [16]. Once more, the pat-
terns of VEGF expression [58] and vasculature profiles [59] differ
between astrogliomas and oligodendrogliomas. Transiently decreas-
ing BEX2 expression in Hs683 cells did not modify VEGF expres-
sion and decreasing IRE-1α expression in these Hs683 cells did not
modify BEX2 expression (data not shown). This suggests that Gal-1–
mediated control of BEX2 is independent of the activation of IRE-1α
and that the BEX2-related effects on angiogenesis and on vasculo-
genic mimicry are therefore IRE-1α–independent. The signaling
pathway by which BEX2 exerts its effects on angiogenesis remains
to be elucidated.
Decreasing BEX2 expression in Hs683 oligodendroglioma cells
markedly impacts cell migration features in vitro on Matrigel or on
fibronectin supports with respect to both cell adhesion and cell inva-
sion (Figure 5). Maniotis et al. [60] suggested that formation of vas-
culogenic mimicry channels is related to the invasive ability of tumor
cells. The fact that decreasing BEX2 expression impairs the invasive
properties of Hs683 glioma cells (Figure 5B) might then partly ex-
plain the effects observed on vasculogenic mimicry in vitro (Figure 4)
and angiogenesis in vivo (Figure 3). The effects observed on cell ad-
hesion and invasion could be partly explained by the fact that de-
creasing BEX2 expression induces the up or down-regulation of a
number of genes involved in migration (Table 2) including notably
MAP2, plexin C1, integrin β6, and SWAP70.
MAP2, a member of the microtubule-associated proteins that can
bind both microtubules and F-actin [61], has been shown to play
a role in cell migration [41,42]. Interestingly, we have shown previ-
ously that the knockdown of Gal-1 expression in U87 astroglioma
cells also decreased their motility and induced an increase in MAP2
expression [12].
Plexin C1 is a member of the plexin family of semaphorin recep-
tors. Semaphorin binding to plexin receptors can regulate actin cyto-
skeleton rearrangement through the regulation of the activity of small
GTPases of the Rho and Rac families [62]. Galectin 1 controls, at
least partly, glioma cell migration through RhoA-mediated modifica-
tions of the actin cytoskeleton [11]. Semaphorins have also been
shown to regulate adhesive and migratory properties of malignant
cells [63], at least through modulation of integrin-mediated adhesion
and migration [48]. Decreasing BEX2 in Hs683 oligodendroglioma
cells induces a marked increase in integrin β6 expression (Figure 6B)
and its clustering in lamelipodia (Figure 6C ). The expression of in-
tegrin β6 has been shown to increase migration and the invasive be-
havior of oral squamous cell carcinomas [43]. Our observation that
the localization of integrin β6 changed toward clustering in lamelipo-
dia (Figure 6C ) when BEX2 expression decreases could possibly ex-
plain the resulting phenotype of increased adhesion (Figure 5A) and
reduced invasion (Figure 5B). We recently showed that depletion of
Gal-1 through both stable knockdown and transient-targeted siRNA
treatment against Gal-1 induces an intracellular accumulation of in-
tegrin β1 coincident with a diminution of integrin β1 at points of cel-
lular adhesion at the cell membrane in Hs683 oligodendroglioma
and U87 astroglioma cells [64]. Galectin 1 depletion does not alter
the gene expression level of integrin β1 but effectuates the perinuclear
accumulation of protein kinase C epsilon and the intermediate fila-
ment vimentin, both of which have been shown to mediate integrin
recycling in motile cells [64].
Finally, it was observed that transiently decreasing BEX2 expres-
sion in Hs683 cells strongly reduced the expression of SWAP70 (Fig-
ure 6), a form of Rac-GEF that transduces signals from tyrosine
kinase receptors to Rac [65]. SWAP70 has been shown to be associ-
ated with a subset of actin filaments generated in lamelipodia and the
membrane ruffles of motile cells [54]. Moreover, SWAP70 has also
been shown to modulate cell adhesion to fibronectin, homotopic cell
aggregation, and migration [55].
Moreover, we have shown that the decrease of Gal-1 expression also
impairs the expression of MAP2 and plexin C1. These results tend to
confirm that Gal-1 could control the expression of BEX2, which, in
turn, modulates the expression of genes involved in cell migration.
In conclusion, the present study has revealed Gal-1–mediated con-
trol of BEX2 expression and the involvement of BEX2 in oligoden-
droglioma neoangiogenesis and oligodendroglioma cell migration. It
is also suggested that these effects may be partly explained by mod-
ulation of the expression of a number of genes such as MAP2, plexin
C1, integrin β6, and SWAP70 that have already been shown to play a
role in cancer cell migration.
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